The Economist asks:
How many RNA vaccines and therapeutics for humans will be FDA-approved as of 2031?
Researchers see a great deal of potential in using ribonucleic acid (RNA) technologies in medicine (Nature, CNN). The outcome will be determined using FDA data available as of 31 December 2031. "Expanded access/compassionate use," "accelerated approval," and "emergency use" authorizations would not count (FDA - Expanded Access, FDA - Accelerated Approval, FDA - Emergency Use Authorization). Approvals of modified formulations of the same vaccine and/or therapeutic to treat different variants of the same disease would not count (e.g., Pfizer getting approval of a modified form of its vaccine to protect against a new variant of COVID-19).